

Barcelona, January 5th 2022

OTHER RELEVANT INFORMATION

Transfer of global rights for Eklira and Duaklir to Covis Pharma completed

In accordance with Securities Markets Law, Almirall, S.A. (“Almirall”) announces the following:

In relation to the communication of other relevant information dated November 1, 2021, with number 12,510 of official record, it is hereby communicated that AstraZeneca has completed the transfer of its global rights to *Eklira* (aclidinium bromide), known as *Tudorza* in the US, and *Duaklir* (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma).

Both medicines are delivered via the *Genuair* device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD).

The agreement will ensure continued patient access to these established medicines.

Almirall will receive \$50m as a result of the transaction. Payment is mostly related to certain changes in the milestone structure initially agreed with AstraZeneca and expected income and cash collection will be recognised in the coming years. Almirall will continue to receive Royalties from the agreement initially signed with AstraZeneca.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com